In re Kiromic BioPharma, Inc.
Securities Litigation

Case No. 1:22-cv-06690 (JHR)
Case Pending in U.S. District Court for the Southern District of New York

Court-Ordered Legal Notice
Forwarding Service Requested

Important Notice about a Securities Class Action Settlement

You may be entitled to a payment.
This Notice may affect your legal rights.

Please read it carefully.

Kiromic BioPharma, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson Street, Ste. 205
Media, PA 19063

The U.S. District Court for the Southern District of New York (the "Court") has preliminarily approved a proposed Settlement of claims against Maurizio Chiriva Internati, Tony Tontat, Gianluca Rotino, Pietro Bersani, Americo Cicchetti, Michael Nagel, Jerry Schneider, Kiromic BioPharma, Inc. ("Kiromic," collectively, the "Kiromic Defendants"). The proposed Settlement would resolve a class action lawsuit against that the Kiromic Defendants only, which alleged the Kiromic Defendants made false and/or misleading misstatements and/or omissions in certain of Kiromic's offering documents concerning the status of Kiromic's investigational new drug applications. The Kiromic Defendants deny the allegations.[1]

You received this notice because you may have purchased or acquired (a) Kiromic common stock pursuant and/or traceable to the Offering Documents (defined in the Settlement) and/or (b) Kiromic common stock between June 25, 2021 and February 2, 2022, both dates inclusive and subject to 15 U.S.C. § 78u-4(e)(1), and you may be a Settlement Class Member. The Settlement provides that, in exchange for dismissal and release of claims against the Kiromic Defendants, a fund consisting of $1,225,000, less attorneys' fees and expenses, will be divided among Settlement Class Members who timely submit valid Proof of Claim and Release Forms ("Proof of Claim") if the Court grants final approval of the Settlement. Plaintiffs believe that the proposed Settlement is fair, reasonable and in the best interests of the Settlement Class. For a full description of the Settlement and your rights and to make a claim, please view the Stipulation of Settlement and obtain a copy of the Notice of Pendency and Proposed Settlement of Class Action, Fairness Hearing and Class Members Rights' ("Notice") and Proof of Claim by visiting the website: www.strategicclaims.net/Kiromic/ (the "Website"). You may request copies of the Notice and Proof of Claim by contacting the Claims Administrator by: (1) mail: Kiromic BioPharma, Inc. Securities Litigation, c/o Strategic Claims Services, 600 N. Jackson St., Ste. 205, P.O. Box 230, Media, PA 19063; (2) call toll-free: 1-866-274-4004; or (3) email: info@strategicclaims.net.

To qualify for payment, you must submit a Proof of Claim to the Claims Administrator, which can be found on the Website. PROOF OF CLAIM FORMS MUST BE POSTMARKED BY DECEMBER 14, 2026 and should be mailed to the address above or submitted electronically by December 14, 2026 at 11:59 p.m. through the Website. If you do not want to be legally bound by the Settlement, you must exclude yourself postmarked no later than November 26, 2026. If you exclude yourself, you cannot get money from this Settlement. If you stay in the Settlement, you may object to it by November 12, 2026. The Notice explains how to exclude yourself or to object.

The Court will hold a hearing in this case on December 17, 2026 at 11:45 a.m. at the United States District Court for the Southern District of New York, Daniel Patrick Moynihan United States Courthouse, 500 Pearl St. Courtroom 12B, New York, NY 10007, to consider whether to approve the Settlement, the Plan of Allocation, and a request by Lead Counsel for no more than 33 1/3% of the Settlement Fund for their attorneys' fees, expenses, and Awards to Plaintiffs. You may, but do not have to, attend the hearing and ask to be heard by the Court. The Court reserves the right to hold the Settlement Hearing telephonically or by other virtual means**.**

[1] For the avoidance of doubt, the claims against ThinkEquity are not being resolved by this Settlement and will continue.